



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_387_24

You asked:

I am conducting analysis on the treatment of severe asthma in secondary care and kindly request your help.

I would be grateful if you could respond with the number of patients treated with specific medicines between the start of April 2024 to the end of June 2024, or the latest three-month period for which data is available. Please include data for all hospitals in the Health Board.

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Please find below, the information Medicines Management are able to provide at this current time. The period the data relates to is 1st April 24 to 30th June 24 and for all hospitals in the Health Board.

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	22
1.2 Dupilumab (Dupixent)	203
1.3 Mepolizumab (Nucala)	78
1.4 Omalizumab (Xolair)	71
1.5 Reslizumab (Cinqaero)	0
1.6 Tezepelumab (Tezspire)	21

Q2. How many patients were treated for severe asthma, atopic dermatitis, CRwNP and other indications with the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic rhinosinusitis with nasal polyps (CRwNP)	Atopic Dermatitis	Other
2.1 Benralizumab (Fasenra)		N/A	N/A	N/A
2.2 Dupilumab (Dupixent)				

2.3 Mepolizumab (Nucala)			N/A	
2.4 Omalizumab (Xolair)			N/A	
2.5 Reslizumab (Cinqaero)		N/A	N/A	N/A
2.6 Tezepelumab (Tezspire)		N/A	N/A	N/A

Unfortunately, we are unable to provide information in relation to question 2 as the Medicines Management system does not record the indication being treated.

We can confirm that the Health Board does not centrally record this information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

Q3. How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Please find below, the information Medicines Management are able to provide at this current time. The period the data relates to is 1st April 24 to 30th June 24 and for all hospitals in the Health Board.

Name of medicine	Respiratory departments	Dermatology departments	Other
3.1 Benralizumab (Fasenra)	22	0	0
3.2 Dupilumab (Dupixent)	10	193	0
3.3 Mepolizumab (Nucala)	78	0	0
3.4 Omalizumab (Xolair)	35	36	0
3.5 Reslizumab (Cinqaero)	0	0	0
3.6 Tezepelumab (Tezspire)	21	0	0

Q4. How many patients were treated for Asthma the following medicines in the 3 months between the start of April 2024 and end of June 2024? Please answer this question for ICS-LABA combination medicines e.g. Symbicort, Seretide and other branded or generic versions of the combination.

Name of medicine	Pack strength	Number of patients
4.1 Fluticasone with salmeterol	All strengths	
4.2 Fluticasone with salmeterol	500mcg fluticasone / 50mcg salmeterol	
4.3 Budesonide with formoterol	All strengths	

4.4 Budesonide with formoterol	400mcg budesonide / 12mcg formoterol	
4.5 Fluticasone with vilanterol	All strengths	
4.6 Fluticasone with vilanterol	184mcg fluticasone / 22mcg vilanterol	
4.7 Beclometasone with formoterol	All strengths	
4.8 Beclometasone with formoterol	200mcg beclomethasone / 6mcg formoterol	
4.9 Fluticasone with formoterol	All strengths	
4.10 Fluticasone with formoterol	250mcg fluticasone / 10mcg formoterol	

Unfortunately, we are not able to provide number of patients for question 4 due to the way the system records information for these medicines. However, we can provide number of issues if this would be a useful alternative (please let us know if required).

To note, the specific information you require (patient numbers) would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.